Publications
308 results found
Ameri P, Bertero E, Lombardi M, et al., 2024, Ischaemic heart disease in patients with cancer., Eur Heart J
Cardiologists are encountering a growing number of cancer patients with ischaemic heart disease (IHD). Several factors account for the interrelationship between these two conditions, in addition to improving survival rates in the cancer population. Established cardiovascular (CV) risk factors, such as hypercholesterolaemia and obesity, predispose to both IHD and cancer, through specific mechanisms and via low-grade, systemic inflammation. This latter is also fuelled by clonal haematopoiesis of indeterminate potential. Furthermore, experimental work indicates that IHD and cancer can promote one another, and the CV or metabolic toxicity of anticancer therapies can lead to IHD. The connections between IHD and cancer are reinforced by social determinants of health, non-medical factors that modify health outcomes and comprise individual and societal domains, including economic stability, educational and healthcare access and quality, neighbourhood and built environment, and social and community context. Management of IHD in cancer patients is often challenging, due to atypical presentation, increased bleeding and ischaemic risk, and worse outcomes as compared to patients without cancer. The decision to proceed with coronary revascularization and the choice of antithrombotic therapy can be difficult, particularly in patients with chronic coronary syndromes, necessitating multidisciplinary discussion that considers both general guidelines and specific features on a case by case basis. Randomized controlled trial evidence in cancer patients is very limited and there is urgent need for more data to inform clinical practice. Therefore, coexistence of IHD and cancer raises important scientific and practical questions that call for collaborative efforts from the cardio-oncology, cardiology, and oncology communities.
AuthorsTask Force Members, McDonagh TA, Metra M, et al., 2024, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC., Eur J Heart Fail, Vol: 26, Pages: 5-17
Document Reviewers: Rudolf A. de Boer (CPG Review Co-ordinator) (Netherlands), P. Christian Schulze (CPG Review Co-ordinator) (Germany), Elena Arbelo (Spain), Jozef Bartunek (Belgium), Johann Bauersachs (Germany), Michael A. Borger (Germany), Sergio Buccheri (Sweden), Elisabetta Cerbai (Italy), Erwan Donal (France), Frank Edelmann (Germany), Gloria Färber (Germany), Bettina Heidecker (Germany), Borja Ibanez (Spain), Stefan James (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Josep Masip (Spain), John William McEvoy (Ireland), Robert Mentz (United States of America), Borislava Mihaylova (United Kingdom), Jacob Eifer Møller (Denmark), Wilfried Mullens (Belgium), Lis Neubeck (United Kingdom), Jens Cosedis Nielsen (Denmark), Agnes A. Pasquet (Belgium), Piotr Ponikowski (Poland), Eva Prescott (Denmark), Amina Rakisheva (Kazakhstan), Bianca Rocca (Italy), Xavier Rossello (Spain), Leyla Elif Sade (United States of America/Türkiye), Hannah Schaubroeck (Belgium), Elena Tessitore (Switzerland), Mariya Tokmakova (Bulgaria), Peter van der Meer (Netherlands), Isabelle C. Van Gelder (Netherlands), Mattias Van Heetvelde (Belgium), Christiaan Vrints (Belgium), Matthias Wilhelm (Switzerland), Adam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) All experts involved in the development of this Focused Update have submitted declarations of interest. These have been compiled in a report and simultaneously published in a supplementary document to the Focused Update. The report is also available on the ESC website www.escardio.org/guidelines See the European Heart Journal online for supplementary documents that include evidence tables.
McDonagh TA, Metra M, Adamo M, et al., 2023, 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure., Eur Heart J, Vol: 44, Pages: 3627-3639
Anker MS, Potthoff SK, Lena A, et al., 2023, Cardiovascular health-related quality of life in cancer: a prospective study comparing the ESC HeartQoL and EORTC QLQ-C30 questionnaire, EUROPEAN JOURNAL OF HEART FAILURE, ISSN: 1388-9842
López-Fernández T, Lyon AR, 2023, Harmonizing the cardiovascular care of adult patients with cancer., Eur Heart J, Vol: 44, Pages: 3019-3020
Lyon AR, Lopez-Fernandez T, Couch LS, et al., 2023, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 23, pg e333, 2022), EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, Vol: 24, Pages: E98-E98, ISSN: 2047-2404
Lena A, Wilkenshoff U, Hadzibegovic S, et al., 2023, Clinical and Prognostic Relevance of Cardiac Wasting in Patients With Advanced Cancer, JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Vol: 81, Pages: 1569-1586, ISSN: 0735-1097
- Author Web Link
- Cite
- Citations: 4
Lyon AR, Lopez-Fernandez T, Couch LS, et al., 2023, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS): Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC) (vol 43, pg 4229, 2022), EUROPEAN HEART JOURNAL, ISSN: 0195-668X
Herrmann J, Lopez-Fernandez T, Lyon AR, 2023, The year in cardiovascular medicine 2022: the top 10 papers in cardio-oncology, EUROPEAN HEART JOURNAL, Vol: 44, Pages: 348-350, ISSN: 0195-668X
- Author Web Link
- Cite
- Citations: 2
Lyon AR, Lopez-Fernandez T, Couch LS, et al., 2023, ESC 2022 guidelines on cardio-oncology in collaboration with the European Hematology Association (EHA), European Society of Therapeutic Radiology and Oncology (ESTRO) and International Cardio-Oncology Society (IC- OS) developed by the Cardio-Oncology Task Force of the European Society of Cardiology (ESC), GIORNALE ITALIANO DI CARDIOLOGIA, Vol: 24, Pages: E1-E130, ISSN: 1827-6806
Couch LS, Lopez-Fernandez T, Lyon AR, 2023, The 'Ten Commandments' for the 2022 European Society of Cardiology guidelines on cardio-oncology, EUROPEAN HEART JOURNAL, Vol: 44, Pages: 10-11, ISSN: 0195-668X
- Author Web Link
- Cite
- Citations: 1
Strongman H, Herrett E, Jackson R, et al., 2023, Cancer history as a predictor in cardiovascular risk scores: a primary care cohort study, BRITISH JOURNAL OF GENERAL PRACTICE, Vol: 73, Pages: E34-E42, ISSN: 0960-1643
Lee GA, Aktaa S, Baker E, et al., 2023, European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment, EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, Vol: 9, Pages: 1-7, ISSN: 2058-5225
- Author Web Link
- Cite
- Citations: 2
Herrmann J, Lopez-Fernandez T, Lyon AR, 2022, The year in cardiovascular medicine 2021: cardio-oncology, COR ET VASA, Vol: 64, Pages: 72-78, ISSN: 0010-8650
Palazzuoli A, Metra M, Collins SP, et al., 2022, Heart failure during the COVID-19 pandemic: clinical, diagnostic, management, and organizational dilemmas, ESC HEART FAILURE, Vol: 9, Pages: 3713-3736, ISSN: 2055-5822
- Author Web Link
- Cite
- Citations: 8
Haanen J, Obeid M, Spain L, et al., 2022, Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up, ANNALS OF ONCOLOGY, Vol: 33, Pages: 1217-1238, ISSN: 0923-7534
- Author Web Link
- Cite
- Citations: 100
Gevaert SA, Halvorsen S, Sinnaeve PR, et al., 2022, Evaluation and management of cancer patients presenting with acute cardiovascular disease: a Clinical Consensus Statement of the Acute CardioVascular Care Association (ACVC) and the ESC council of Cardio-Oncology-part 2: acute heart failure, acute myocardial diseases, acute venous thromboembolic diseases, and acute arrhythmias, EUROPEAN HEART JOURNAL-ACUTE CARDIOVASCULAR CARE, Vol: 11, Pages: 865-874, ISSN: 2048-8726
- Author Web Link
- Cite
- Citations: 7
Andres MS, Ramalingam S, Rosen SD, et al., 2022, The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment Including myocarditis and the new entity of non inflammatory left ventricular dysfunction, CARDIO-ONCOLOGY, Vol: 8
- Author Web Link
- Cite
- Citations: 4
Quinaglia T, Gongora C, Awadalla M, et al., 2022, Global Circumferential and Radial Strain Among Patients With Immune Checkpoint Inhibitor Myocarditis, JACC-CARDIOVASCULAR IMAGING, Vol: 15, Pages: 1883-1896, ISSN: 1936-878X
- Author Web Link
- Cite
- Citations: 6
Farhan HA, Yaseen IF, Alomar M, et al., 2022, Global pattern of cardiovascular disease management in patients with cancer and impact of COVID-19 on drug selection: IRAQ-IC-OS survey-based study, FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol: 9, ISSN: 2297-055X
Lyon AR, Lopez-Fernandez T, Couch LS, et al., 2022, 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) Developed by the task force on cardio-oncology of the European Society of Cardiology (ESC), EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, Vol: 23, Pages: E333-E465, ISSN: 2047-2404
- Author Web Link
- Cite
- Citations: 23
Tranter MH, Redfors B, Wright PT, et al., 2022, Hyperthermia as a trigger for Takotsubo syndrome in a rat model (vol 9, 869585, 2022), FRONTIERS IN CARDIOVASCULAR MEDICINE, Vol: 9, ISSN: 2297-055X
Nazir MS, Okafor J, Murphy T, et al., 2022, LVEF MEASURED WITH SAME DAY ECHOCARDIOGRAPHY AND CMR IN PATIENTS WITH SUSPECTED CARDIOTOXICITY, BSCI/BSCCT Annual Meeting, Publisher: BMJ PUBLISHING GROUP, Pages: A11-A11, ISSN: 1355-6037
Tranter MH, Redfors B, Wright PT, et al., 2022, Hyperthermia as a trigger for Takotsubo syndrome in a rat model, Frontiers in Cardiovascular Medicine, Vol: 9, Pages: 1-9
Takotsubo syndrome is a well-characterized cause of acute yet reversible heart failure associated with periods of intense emotional stress, often mimicking on presentation an acute coronary syndrome. Animal models of Takotsubo syndrome have been developed, either through the application of a stressor, or administration of exogenous catecholamine. We found that in a model of isoproterenol-induced Takotsubo syndrome in anesthetized rats hyperthermia (40–41°C) would occur after the administration of isoproterenol. Maintenance of this hyperthermia would result in an apical hypocontractility typical of the syndrome, whereas prevention of hyperthermia with active cooling to maintain a euthermic core body temperature prevented (but did not subsequently reverse) apical hypocontractility. In vitro experimentation with isolated cardiomyocytes showed no effect of hyperthermia on either baseline contractility or contractility change after beta-adrenoceptor stimulation. We suggest that the rise in body temperature that is characteristic of catecholamine storm may be a component in the development of Takotsubo syndrome.
McDonagh TA, Metra M, Adamo M, et al., 2022, Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureGrupo de Trabajo de la Sociedad Europea de Cardiología (ESC) de diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónicaDesarrollada con la colaboración especial de la Heart Failure Association (HFA) de la ESC, Revista Espanola de Cardiologia, Vol: 75, Pages: 523.e1-523.e114, ISSN: 0300-8932
- Cite
- Citations: 12
Maraldo M, Levis M, Andreis A, et al., 2022, An integrated approach to cardioprotection in lymphomas, LANCET HAEMATOLOGY, Vol: 9, Pages: E445-E454, ISSN: 2352-3026
- Author Web Link
- Cite
- Citations: 4
McDonagh TA, Metra M, Adamo M, et al., 2022, 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC., Rev Esp Cardiol (Engl Ed), Vol: 75
Couch LS, Fiedler J, Chick G, et al., 2022, Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure, Cardiovascular Research, Vol: 118, Pages: 1758-1770, ISSN: 0008-6363
AIMS: Takotsubo syndrome (TTS) is an acute heart failure, typically triggered by high adrenaline during physical or emotional stress. It is distinguished from myocardial infarction (MI) by a characteristic pattern of ventricular basal hypercontractility with hypokinesis of apical segments, and absence of coronary occlusion. We aimed to understand whether recently discovered circulating biomarkers miR-16 and miR-26a, which differentiate TTS from MI at presentation, were mechanistically involved in the pathophysiology of TTS. METHODS AND RESULTS: miR-16 and miR-26a were co-overexpressed in rats with AAV and TTS induced with an adrenaline bolus. Untreated isolated rat cardiomyocytes were transfected with pre-/anti-miRs and functionally assessed. Ventricular basal hypercontraction and apical depression were accentuated in miR-transfected animals after induction of TTS. In vitro miR-16 and/or miR-26a overexpression in isolated apical (but not basal) cardiomyocytes produced strong depression of contraction, with loss of adrenaline sensitivity. They also enhanced the initial positive inotropic effect of adrenaline in basal cells. Decreased contractility after TTS-miRs was reproduced in non-failing human apical cardiomyocytes. Bioinformatic profiling of miR targets, followed by expression assays and functional experiments, identified reductions of CACNB1 (L-type calcium channel Cavβ subunit), RGS4 (regulator of G-protein signalling 4) and G-protein subunit Gβ (GNB1) as underlying these effects. CONCLUSION: miR-16 and miR-26a sensitise the heart to TTS-like changes produced by adrenaline. Since these miRs have been associated with anxiety and depression, they could provide a mechanism whereby priming of the heart by previous stress causes an increased likelihood of TTS in the future. TRANSLATIONAL PERSPECTIVE: TTS-associated miRs have the potential to be active players predisposing to TTS. Feasibly, their measurement in recovered TTS patients during subsequent peri
Seferovic PM, Tsutsui H, McNamara DM, et al., 2022, Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy (vol 23, pg 854, 2021), EUROPEAN JOURNAL OF HEART FAILURE, Vol: 24, Pages: 732-732, ISSN: 1388-9842
Sliwa K, van der Meer P, Petrie MC, et al., 2022, Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy (vol 23, pg 527, 2021), EUROPEAN JOURNAL OF HEART FAILURE, Vol: 24, Pages: 733-733, ISSN: 1388-9842
- Author Web Link
- Cite
- Citations: 1
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.